LON:DEST - Destiny Pharma Stock Price, News & Analysis

GBX 39.90
+0.40 (+1.01 %)
(As of 08/19/2019 08:01 AM ET)
Today's Range
Now: GBX 39.90
50-Day Range
MA: GBX 65.68
52-Week Range
Now: GBX 39.90
Volume51,215 shs
Average Volume4,205 shs
Market Capitalization£17.48 million
P/E RatioN/A
Dividend YieldN/A
Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections. Read More…

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A
Cash FlowGBX 27.98 per share
Book ValueGBX 28.10 per share



Market Cap£17.48 million
Next Earnings DateN/A

Receive DEST News and Ratings via Email

Sign-up to receive the latest news and ratings for DEST and its competitors with MarketBeat's FREE daily newsletter.

Destiny Pharma (LON:DEST) Frequently Asked Questions

What is Destiny Pharma's stock symbol?

Destiny Pharma trades on the London Stock Exchange (LON) under the ticker symbol "DEST."

How were Destiny Pharma's earnings last quarter?

Destiny Pharma PLC (LON:DEST) announced its quarterly earnings results on Tuesday, April, 9th. The company reported ($11.90) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($16.20) by $4.30. View Destiny Pharma's Earnings History.

Has Destiny Pharma been receiving favorable news coverage?

Headlines about DEST stock have trended negative this week, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Destiny Pharma earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Destiny Pharma.

Who are some of Destiny Pharma's key competitors?

What other stocks do shareholders of Destiny Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Destiny Pharma investors own include African Potash (AFPO), LiDCO Group (LID), Satellite Solutions Worldwide (SAT), Banco Santander (SAN), Futura Medical (FUM), Fulcrum Utility Services (FCRM), eve Sleep (EVE), DX (Group) (DX), Coro Energy (CORO) and Biopharma Credit (BPCR).

Who are Destiny Pharma's key executives?

Destiny Pharma's management team includes the folowing people:
  • Mr. Neil Robert Clark, CEO & Director (Age 56)
  • Dr. William Guy Love, Founder, Chief Scientific Officer & Director (Age 56)
  • Mr. Shaun Claydon, CFO, Company Sec. & Director (Age 51)
  • Dr. Jesús M González Moreno, Chief Medical Officer

How do I buy shares of Destiny Pharma?

Shares of DEST and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Destiny Pharma's stock price today?

One share of DEST stock can currently be purchased for approximately GBX 39.90.

How big of a company is Destiny Pharma?

Destiny Pharma has a market capitalization of £17.48 million. View Additional Information About Destiny Pharma.

What is Destiny Pharma's official website?

The official website for Destiny Pharma is http://www.destinypharma.com/.

How can I contact Destiny Pharma?

Destiny Pharma's mailing address is Sussex Innovation Centre Science Park Square, Falmer, BRIGHTON, BN1 9SB, United Kingdom. The company can be reached via phone at +44-1273-704440.

MarketBeat Community Rating for Destiny Pharma (LON DEST)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  127
MarketBeat's community ratings are surveys of what our community members think about Destiny Pharma and other stocks. Vote "Outperform" if you believe DEST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DEST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel